Xanthelasma palpebrarum: a new side effect of nilotinib

Chronic myeloid leucaemia (CML) is a chronic myeloproliferative disorder characterised by a reciprocal translocation between the chromosomes 9and 22 resulting in constitutionally active tyrosine kinasesignalling. BCR-ABL tyrosine kinase inhibitors(TKIs) are highly effective molecules in the treatment of CML. Unfortunately, these novel therapeutic agents are accompanied by various side effects, and haematological, cutaneous and metabolic abnormalities are among the most prevalent. Nilotinib, a second-generation TKI, has been shown to cause both—cutaneous lesions and lipid profile abnormalities. We present two CML cases developing xanthelasmapalpebrarum while receiving nilotinib. Case 1 also acquired a lipid abnormality following the start of nilotinibtherapy, while case 2 meanwhile stayed normolipidemic. In addition to a low cholesteroldiet, atorvastatinwas prescribed to case 1. Currently, both cases are normolipidemic and continuing their nilotinibtherapy. Xanthelasmapalpebrarum secondary to nilotinibtherapy is new to the literature.